- from the UK MHRA. On June 9, 2010,
Astellas acquired OSI
Pharmaceuticals for $4.0 billion. In
December 2014,
Astellas expanded its 18-month-old collaboration...
- Year
Ended March 31, 2021
Annual Report 2021 (PDF) (Report).
Astellas. 31
March 2020. "
Astellas Pharma Inc.
Annual Report 2018" (PDF). www.
astellas.com....
-
Astellas Pharma Inc". www.
astellas.com.
Summary in ****anese.
Retrieved on
September 4, 2012. "2013 News
Releases |
Astellas Pharma Inc". www.
astellas...
- 27
September 2024. "
Astellas'
Vyloy (zolbetuximab)
Approved in ****an for
Treatment of
Gastric Cancer" (Press release).
Astellas Pharma. 26
March 2024...
- and scientist,
currently Head of
Astellas Global Regenerative Medicine, and
Chief Scientific Officer of the
Astellas Institute for
Regenerative Medicine...
- (PDF).
Astellas Pharma Inc. 31
March 2014.
Archived from the
original (PDF) on 4
September 2019.
Retrieved 12
November 2016. "About
Astellas".
Astellas Pharma...
-
product pipeline includes enfortumab vedotin,
being co-developed with
Astellas Pharma,
tisotumab vedotin,
being co-developed with Genmab, SGN-LIV1A, an...
-
fully humanized antibody was
created by
scientists at
Agensys (part of
Astellas)
using Xenomice from Amgen; the
linker technology holding the antibody...
-
Astellas Institute for
Regenerative Medicine is a
subsidiary of
Astellas Pharma located in Marlborough, M****achusetts, US,
developing stem cell therapies...
- from this source,
which is in the
public domain. "
Astellas to
Acquire Ogeda SA" (Press release).
Astellas Pharma.
Archived from the
original on 5 November...
